Curated regulatory guidance, clinical analyses, and market reports. AI-summarized, editor-reviewed, instantly downloadable.
Research Pulse
Aggregated from live regulatory feedsNovaPharmaNews hosts 36 curated pharmaceutical whitepapers and industry reports from 8 publishers — FDA and EMA regulatory guidance, clinical analyses, manufacturing intelligence, and market research. 3 featured reports are editor-picked this week. Each landing page includes key takeaways, optional PDF download, and links to related drugs, companies, and pipeline data.
Methodology & data sources Publications & analysis Editorial policy
🔒 ★ Optimizing Pharmaceutical Manufacturing: The Critical Role of Dew Point Monitoring
Dew point monitoring is crucial for controlling humidity in sensitive industrial environments where even trace moisture can compromise produ…
🔒 ★ Pharma R&D ROI: A Multidimensional Framework for AI Investment Success
Top pharma companies are adopting a multidimensional ROI framework that combines scientific, operational, and commercial metrics to evaluate…
🔒 ★ Navigating Human Research: Mass General Brigham's IRB Guidance for Ethical Clinical Trials
IRBs provide an independent, ethics-focused evaluation of proposed research, including checks on clinical investigators' potential biases ( …
🔒 ★ National Drug Control Strategy (2026): A Comprehensive Approach to Combat Drug Addiction
The strategy addresses the fentanyl crisis as a national emergency.
★ FDA Seeks Input on Drug Repurposing for Unmet Medical Needs
FDA is establishing a public docket for drug repurposing input.
🔒 America's Innovation Engine: Small and Mid-Sized Biotechs Drive U.S. Clinical Trials, FDA Filings
Small and mid-sized biotechs represent approximately 99% of U.S. biotech business establishments and account for 71% of total industry emplo…
🔒 FDA CBER Patient Listening Meeting on Gene Therapy Safety: Patient and Care Partner Perspectives
FDA CBER held a dedicated patient listening meeting focused on two core themes: safety considerations in gene therapy treatment decisions an…
🔒 BIO 2025 Report: U.S. Bioscience Industry Policy Guide for State Growth
States are adopting phase-specific policy approaches tailored to company development stage, from discovery and seed through commercializatio…
🔒 ICH Technology Platform Report: Secure Collaboration Requirements for Regulatory Harmonisation
A single cloud-based platform hosted in Switzerland would enable secure, temporary sharing of commercially confidential information between …
🔒 Digital Money report summary: monetary architecture, CBDC, stablecoins and regulation
Digital money is fundamentally an institutional and policy issue, not merely a technical one. The critical questions concern who creates mon…
🔒 Institutional Recognition of SoTL in Health Professions Education: Scoping Review for Education
SoTL is described with shared core concepts across health professions education literature, but operationalized in varied ways that often bl…
🔒 WHO Revised Biosimilar Guidelines: Streamlined Regulation for Improved Global Access
WHO's 2022 revised guidelines eliminate the need for mandatory clinical efficacy studies for biosimilars when strong analytical and pharmaco…
🔒 Precision Prevention: UK Government's Role in Unlocking Biology-Based Cancer Prevention Research
Currently, 40% of cancers are preventable via known risk factors; precision prevention could increase this proportion by targeting the biolo…
🔒 The ICAOS, effective since 2002, replaced the 1937 Interstate Compact for Probation and Parole (ICPP) and serves as binding federal law gove…
Mitigating Prior Authorization Burdens: Insights from Reference Committee G
Ninety-three percent of physicians report delays in patient care due to prior authorization.
Digital Transformation in Pharma CRM: Enhancing HCP Engagement
Digital channels are increasingly preferred by HCPs over traditional in-person interactions.
RYBREVANT® Access and Reimbursement Guide Overview
RYBREVANT® is indicated for specific NSCLC mutations, including EGFR exon 19 deletions, exon 21 L858R substitution mutations, and exon 20 in…
Guidance on Developing Treatments for Stimulant Use Disorders
FDA has not yet approved any medications for stimulant use disorders.
Our research library curates FDA, EMA, and industry publisher PDFs — regulatory guidance, clinical analyses, manufacturing reports, and market intelligence. Each report includes an AI-summarized landing page with key takeaways and a gated PDF download.
Open any report page, scroll to the download form, and enter your work email. You receive instant PDF access and can opt in to weekly pharma intelligence updates. Downloads are free for healthcare professionals.
Report pages link to related intelligence — company profiles, drug INN pages, clinical trials, pipeline programs, and topic hubs. Use the intelligence spokes on each page to explore the entity graph behind the research.
New reports are ingested daily from leading publishers and regulatory sources. Featured picks highlight high-impact FDA, EMA, and industry research each week.